about
Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of ProgressThe effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specificBovine leukemia virus-induced lymphocytosis and increased cell survival mainly involve the CD11b+ B-lymphocyte subset in sheep.Pleiotrophin commits human bone marrow mesenchymal stromal cells towards hypertrophy during chondrogenesisBiologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study.Percutaneous injection of bone marrow mesenchymal stem cells for ankle non-unions decreases complications in patients with diabetes.Development of a simple procedure for the treatment of femoral head osteonecrosis with intra-osseous injection of bone marrow mesenchymal stromal cells: study of their biodistribution in the early time points after injectionOsteogenic progenitors in bone marrow aspirates have clinical potential for tibial non-unions healing in diabetic patients.Local transplantation of bone marrow concentrated granulocytes precursors can cure without antibiotics infected nonunion of polytraumatic patients in absence of bone defect.Allografts supercharged with bone-marrow-derived mesenchymal stem cells possess equivalent osteogenic capacity to that of autograft: a study with long-term follow-ups of human biopsies.Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells.Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy.Osteonecrosis repair with bone marrow cell therapies: state of the clinical art.Autologous bone marrow stromal cells are promising candidates for cell therapy approaches to treat bone degeneration in sickle cell disease.ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.In vitro characterization of patches of human mesenchymal stromal cells.Muscle acellular scaffold as a biomaterial: effects on C2C12 cell differentiation and interaction with the murine host environment.Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate.Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.Inferior In Vivo Osteogenesis and Superior Angiogeneis of Human Adipose Tissue: A Comparison with Bone Marrow-Derived Stromal Stem Cells Cultured in Xeno-Free Conditions.Enhanced human bone marrow mesenchymal stromal cell adhesion on scaffolds promotes cell survival and bone formation.Cell Colonization Ability of a Commercialized Large Porous Alveolar Scaffold.Single-stage treatment of infected tibial non-unions and osteomyelitis with bone marrow granulocytes precursors protecting bone graft.Stem cell therapy in early post-traumatic talus osteonecrosis.B-1-like cells exist in sheep. Characterization of their phenotype and behaviour.Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial.Bone-Forming Capacity and Biodistribution of Bone Marrow-Derived Stromal Cells Directly Loaded Into Scaffolds: A Novel and Easy Approach for Clinical Application of Bone Regeneration.Dynamic mesenchymal stem cells volumic seeding in a commercialized porous ceramic scaffold: a feasibility study.Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression.Supercharging irradiated allografts with mesenchymal stem cells improves acetabular bone grafting in revision arthroplasty.The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.Inferior In Vivo Osteogenesis and Superior Angiogenesis of Human Adipose-Derived Stem Cells Compared with Bone Marrow-Derived Stem Cells Cultured in Xeno-Free Conditions.History of concentrated or expanded mesenchymal stem cells for hip osteonecrosis: is there a target number for osteonecrosis repair?[Mesenchymal stromal cells: Biological properties and clinical prospects]In vivo and in vitro comparison of three different allografts vitalized with human mesenchymal stromal cellsCancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrateNew preclinical porcine model of femoral head osteonecrosis to test mesenchymal stromal cell efficiency in regenerative medicineRegenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence?Subchondral stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the kneeCell therapy versus simultaneous contralateral decompression in symptomatic corticosteroid osteonecrosis: a thirty year follow-up prospective randomized study of one hundred and twenty five adult patients
P50
Q26765198-29809C2B-4F14-41ED-BF6A-AE5E36E9891EQ28216343-94F8C776-950E-4834-B40F-6BA2D5D3075BQ33782898-82029AEB-9016-44A7-9384-5CCBFA1575ABQ35091670-B8DC70AF-C2D6-40D6-B1E3-02F8D1194766Q35184468-B204F959-410D-4F95-BD8E-D23B62391B43Q35582983-F41DB607-1AAB-4961-BDCD-5A0C98A32D9EQ35663230-A0273910-C901-451C-BC00-19A4D19A9A6DQ35842743-71774885-07C3-42B2-A6E1-170F5E096996Q35940359-37581BD3-E725-4589-9E34-A29C839F7675Q36112104-B436BDC4-C9BF-4853-8616-FC16ED7FF0AFQ37300254-74FF5671-60FF-46AD-A79E-8FF889A37B08Q38198538-3F568950-F8AF-42B1-AA86-9782FAA4A6E5Q38228753-C1D923CA-2A64-4FC0-B866-78D20943618DQ40402621-1188944C-29AC-438D-B6FA-31D8CBE3DE3AQ40627341-E0EF98BB-B2E8-4997-99D5-FFBF97CD92EBQ42556359-23603351-5470-4159-A991-7984C859B6B2Q42917523-7149C2D2-B8CD-4E1F-BCF6-821DF4A43332Q43270810-482E350A-DCD5-4EC7-A694-E4F67281DB1CQ44214843-FD682624-E0C1-4665-8783-6F6DCA59D08FQ47111498-F8550D41-871B-4C79-AAB9-E871A30D1E83Q47998066-F5A5B6BF-6C96-4D09-A084-3162DDD28816Q48130121-3D54AEBA-4F20-4B6E-9A54-79C9BA404888Q50039419-7A60529A-0ED7-47F8-A463-76B11D9564F0Q50117845-A0F5074A-47CC-4A06-952E-AD0CBFE5D6C0Q52182159-30BC7EC5-A07F-48E9-B0B0-7FE35603550DQ52621157-C2308683-8CC6-4C00-BED2-091BACE8324FQ53402365-39E8F1A2-B10F-4567-8A36-AD2755B4F603Q53487644-56A44E4D-DA31-4549-88F3-A987BE10860DQ53610680-CA89CA3C-DAF5-491F-B799-E27A274D8A9FQ53623785-5DB2BB73-2ADE-4563-BE84-E5757D8BC46BQ54509665-B89D7735-8A6D-4E3D-AEB9-2EEECBADBCCBQ55276208-2F72AD77-035D-472F-AE9A-642C52A76B88Q57178280-6DCD7677-1BB4-4B95-A73B-AD273519E574Q83514683-430C0486-C65D-4EC9-9EF9-546E90E24519Q84071756-5D800AD3-F1F7-4372-BD2A-66E13A885E46Q86976368-548A9A79-2A78-45E3-933D-A62787B00955Q87841701-F83E60A7-40E2-4CEB-B812-A646CEAE07E0Q88034954-1257170D-841B-4F51-99ED-02521ACB5D46Q88197101-555FF15E-3EC5-424F-A50A-D8D98F8508B5Q88621971-9B95B00B-3F80-405D-9920-1D3C17A19F13
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nathalie Chevallier
@ast
Nathalie Chevallier
@en
Nathalie Chevallier
@es
Nathalie Chevallier
@nl
type
label
Nathalie Chevallier
@ast
Nathalie Chevallier
@en
Nathalie Chevallier
@es
Nathalie Chevallier
@nl
prefLabel
Nathalie Chevallier
@ast
Nathalie Chevallier
@en
Nathalie Chevallier
@es
Nathalie Chevallier
@nl
P106
P21
P31
P496
0000-0002-1800-2579